Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity.

Trial Profile

Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2016

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-Eating Disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LDX in BED
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Parent trial: NCT01090713)
    • 13 Aug 2012 New source identified (ClinicalTrials.gov record NCT01657019 - extension study)
    • 12 Apr 2012 Planned end date changed from 1 May 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top